Medtronic plc (MDT) Stock: Price, Forecast & Analyst Target
Medtronic plc (MDT) — MoonshotScore 81/100 (Exceptional band), calculated Nov 18, 2026. Price $100.72 (-1.56%), as of the Nov 18, 2026 trading session; market cap $129B. Expected results Nov 24, 2026.
Educational signal · not a buy or sell recommendation · How to read this
Medtronic plc · MDT · NYSE · Healthcare · Medical - Devices
Research dated 2026-09-12: Medtronic sells device-based therapies spanning cardiovascular care, surgery, neuroscience, and diabetes, with revenue tied to procedures, implanted systems, clinical platforms, monitoring, and recurring consumables. The case now depends on whether expanding sales can produce durable operating leverage without gross-profit pressure or uneven cash conversion weakening the result.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Medtronic (MDT)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Nov 24, 2026
- Altman Z 3.17 · Piotroski F 9
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 81 | Exceptional | |
| 80 | Strong | |
| 81 | Exceptional | |
| 81 | Exceptional | |
| 81 | Exceptional | |
| 81 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $100.72 | |
| Change on the day | -1.56% | |
| 52-week range | $73.31–$106.33 | |
| Market capitalisation | $129B | — |
| Price / earnings (trailing) | 25.08 | |
| Shares traded on the day | 6.47M | |
| Beta (volatility vs the S&P 500) | 0.57 |
Why Medtronic scores 81
Share price, last 12 months -3.3%
$95.92 $92.77
What the price assumes
6.7% a year of free-cash-flow growth for ten years is what a $118.67B market value ( snapshot) asks for.
The price asks for faster cash-flow growth than Medtronic has delivered. That depends on new products.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $6.13B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 9 of the last 12 reports (2023–2026); the stock still fell the next session after 3 of those beats. Average first-session move: 4.0% either way.
- +4.3%Nov ’23
- +1.8%Feb ’24
- -4.0%May ’24
- +3.2%Aug ’24
- -4.0%Nov ’24
- -6.3%Feb ’25
- -6.3%May ’25
- +0.4%Aug ’25
- +4.2%Nov ’25
- -1.0%Feb ’26
- +11.1%Jun ’26
- +1.7%Sep ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | Beat | +1.7% | +1.4% | |
| In line | Beat | +11.1% | +8.8% | |
| Beat | Beat | -1.0% | -2.8% | |
| Beat | Beat | +4.2% | +9.4% | |
| Beat | Beat | +0.4% | -0.7% | |
| Beat | Beat | -6.3% | -4.6% | |
| Beat | In line | -6.3% | -2.5% | |
| In line | Beat | -4.0% | -2.2% | |
| Beat | Beat | +3.2% | +4.7% | |
| In line | Beat | -4.0% | -5.1% | |
| Beat | Beat | +1.8% | -0.7% | |
| Beat | In line | +4.3% | +4.9% |
Medtronic beats routinely, and the market rewards it.
What management is saying differently
Management's own words on the Q1 FY2027 call () against Q4 FY2026 (). Analysts' questions are left out.
- New this call: “soft tissue”, “growth opportunities”, “med tech”, “high-volume centers” — none of them came up in Q4 FY2026.
- Getting louder: “touch surgery” (2 → 8 mentions), “capital allocation” (3 → 7 mentions).
- Gone quiet: “excluding tariffs”, “physician feedback”, “single-digit growth”, “clinical outcomes” — regular themes last call, absent this time.
- Tone: Cautious words such as “may”, “could” and “headwind” fell from 2.9 to 1.3 per 1,000 words, and confident words such as “record” and “strong” fell from 8.4 to 6.9.
Management sounded more assured, with surgical robotics and high-volume centers new themes.
Our track record on this stock
Since the score went from 77 to 81 while the share price moved +8.4% through .
| Date | Band | 3 months | 6 months | Call |
|---|---|---|---|---|
| Strong → Exceptional | — | — | — | |
| Exceptional → Strong | — | — | — | |
| Strong → Exceptional | — | — | — | |
| Exceptional → Strong | — | — | — | |
| Strong → Exceptional | — | — | — | |
| Exceptional → Strong | — | — | — |
None of the 7 band changes we have recorded has been graded yet; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 61% of 51 rate it a buy; the average target sits -3.0% from the price of $100.72.
- Last 90 days: 1 upgrade and 0 downgrades among 15 rating actions.
- Our signals: Exceptional band; strongest pillar Momentum (86), weakest Financial Safety (54).
Analysts and our signals both lean positive on the device maker. Their modest targets reflect a company that grows slowly but reliably.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Medtronic (MDT): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Medtronic (MDT), and what does it report?
Short answer · as of
Medtronic plc is more than a conventional medical-device manufacturer.
Research dated 2026-09-12.
Its portfolio reaches from pacemakers, defibrillators, valves, and stent grafts to surgical instruments, robotic guidance, imaging, ventilation, insulin pumps, glucose monitoring, and the consumables and software attached to those therapies.
Reported revenue therefore measures a blend of implant demand, procedure activity, equipment and instrument use, patient monitoring, and recurring diabetes supplies. Cardiovascular contributes the largest segment base, followed by neuroscience and medical surgical, while diabetes is smaller but carries a distinct consumables component.
The income statement reflects the combined portfolio rather than a uniform product cycle. Annual revenue and net income have advanced recently, while quarterly profit and cash flow still fluctuate enough to make operating leverage more informative than sales growth alone.
What do the latest results show for Medtronic (MDT)?
Research dated 2026-09-12.
The latest quarter extended year-over-year revenue growth even as sales eased from the immediately preceding period. Operating profit, net income, and diluted earnings improved against the preceding quarter and year-earlier period, but gross profit retreated sequentially, leaving a stronger bottom line without uniform improvement across the statement.
Reported revenue and adjusted earnings cleared consensus, continuing a pattern of adjusted earnings finishing above expectations. That record shows dependable execution against forecasts, while the gross-profit and operating-cash-flow series show why headline beats alone do not establish improving economics.
Management has committed to operating-profit growth and margin expansion and describes the full-year model as leveraged. That is a forward commitment rather than an explanation for the latest change, and it will be tested by the relationship among revenue, gross profit, operating expenses, and cash generation.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jul 31, 2026 | Not available | Not available | Not available | Not available |
| Apr 30, 2026 | Not available | Not available | Not available | Not available |
| Jan 31, 2026 | Not available | Not available | Not available | Not available |
| Oct 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $9.76B Sep 1, 2026
- Latest report · revenue estimate
- $9.55B Sep 1, 2026
- Latest report · revenue vs estimate
- Above estimate Sep 1, 2026
- Latest report · EPS vs estimate
- Above estimate Sep 1, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Sep 1, 2026 | $9.76B | $9.55B | $1.4500 | $1.3900 |
| Jun 3, 2026 | $9.81B | $9.62B | $1.5500 | $1.5400 |
| Feb 17, 2026 | $9.02B | $8.91B | $1.3600 | $1.3400 |
| Nov 18, 2025 | $8.96B | $8.87B | $1.3600 | $1.3100 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Jul 2025 | $8.58B | $1.04B | $0.81 (diluted) |
| Oct 2025 | $8.96B | $1.37B | $1.07 (diluted) |
| Jan 2026 | $9.02B | $1.14B | $0.89 (diluted) |
| Apr 2026 | $9.81B | $1.24B | $0.97 (diluted) |
What are the financial strengths and risks for Medtronic (MDT)?
Short answer
Cash and short-term investments were $0.00 at the Jul 31, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Liquidity is substantial and near-term coverage ratios are comfortable, but cash and investments do not offset total debt. The balance sheet is therefore liquid rather than debt-free, with a meaningful net debt position despite a cash balance that remains above much of its recent range.
Operating cash flow has remained positive, and capital spending has consumed a minority of that inflow in every displayed period. Cash conversion is uneven across quarters, however, so a strong period should not be treated as the normal run rate.
The operating risk is visible in the latest cost structure: stable sequential revenue coincided with lower gross profit and higher selling and administrative expense. If that combination persists, it would work directly against management’s leverage objective; weakness in cardiovascular procedures would matter especially because that portfolio supplies the largest segment contribution.
What should you watch next at Medtronic (MDT)?
Short answer · as of
The next earnings report is expected on Nov 24, 2026. The number it tests is the $5.52 EPS analysts carry for it.
Research dated 2026-09-12.
The next results should be read through gross profit and operating expense behavior, not merely the adjusted earnings comparison. Revenue holding near its recent level would carry more weight if operating profit expands without another sequential gross-profit setback or disproportionate growth in selling and administrative costs.
Cash conversion deserves a separate check. Operating cash flow has varied sharply despite steadier capital spending, while cash and short-term investments slipped from the latest peak and debt remains far larger than liquid resources.
Longer-range consensus embeds continued revenue and earnings expansion. Evidence for that path would be broader segment growth accompanied by rising operating profit and cash flow, especially if cardiovascular remains the main contributor and diabetes adds recurring pump and monitoring demand.
How does Medtronic compare with its peers?
Short answer
Medtronic's score ranks tied for 8th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Medtronic differs from a narrowly focused device maker because its revenue spans implantable cardiac therapies, surgical tools and platforms, neuroscience systems, patient monitoring, and diabetes devices with associated consumables. The portfolio mixes procedure-linked products, durable clinical systems, software-enabled monitoring, and repeat-use supplies rather than relying on a uniform purchasing pattern.
Cardiovascular remains the economic anchor, but neuroscience and medical surgical also carry material scale, while diabetes contributes a smaller and more recurring product relationship. That breadth reduces dependence on a narrowly defined therapy while making consolidated margins sensitive to portfolio mix and spending across several development programs.
Established profitability, positive free cash generation, and sustained research spending characterize Medtronic more accurately than a high-growth device profile. Its relevant comparison is therefore with diversified medical-technology platforms whose value depends on steady clinical adoption and operating discipline across mature and developing franchises.
| Company | Price | Market value | Score |
|---|---|---|---|
| $105.23 Nov 18, 2026 | $60.5B | 93 5-pillar Nov 18, 2026 | |
| $80.19 Nov 19, 2026 | $29.9B | 93 5-pillar Nov 18, 2026 | |
| $536.45 Nov 18, 2026 | $136B | 90 5-pillar Nov 18, 2026 | |
| $47.12 Nov 18, 2026 | $113B | 87 5-pillar Nov 18, 2026 | |
| $259.57 Nov 18, 2026 | $25.2B | 87 5-pillar Nov 18, 2026 | |
| $59.56 Nov 18, 2026 | $122B | 85 5-pillar Nov 18, 2026 | |
| $30.32 Nov 18, 2026 | $12.7B | 84 5-pillar Nov 18, 2026 | |
| Medtronic (MDT) — this page | $100.72 | $129B | 81 |
| $80.06 Nov 19, 2026 | $102B | 81 5-pillar Nov 18, 2026 | |
| $318.15 Nov 18, 2026 | $121B | 80 5-pillar Nov 18, 2026 | |
| $103.32 Nov 18, 2026 | $19.6B | 79 5-pillar Nov 18, 2026 | |
| $29.27 Nov 19, 2026 | $28.6B | 78 5-pillar Nov 18, 2026 | |
| $48.58 Nov 18, 2026 | $97.4B | 77 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $83.00 – $120.00
- Consensus target
- $100.69
- Median target
- $99.00
- Revenue estimate
- $36.15B
- EPS estimate
- $5.52
Consensus record · Captured .
Measured against a quoted price of $100.72 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 2, 2026
- Transactions
- 62
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 6
- Other transactions
- 56
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MDT in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.18% | $42.11M | Added +1.1% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Medtronic (MDT)?
- Connected Health Devices - Global Strategic Business Report 2026: Capitalize on 21.3% CAGR and $11.6B Revenue Opportunity by 2032 with Apple, Medtronic, Microsoft, Roche and Epic Systems
- Global Clinical-Grade Wearables for Pharma and Biotech Market Report 2026 | Capitalize on 21.5% CAGR to $7.48B by 2030 as Abbott, Medtronic, DexCom and Philips Scale AI-Driven RPM
Medtronic Healthcare Stock: Key Questions Answered
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What makes Medtronic more than a pacemaker company?
Pacemakers sit inside a much broader cardiovascular franchise, while surgical instruments, robotic and imaging systems, neuroscience therapies, ventilation, patient monitoring, insulin pumps, glucose monitoring, and recurring consumables extend the business across many clinical workflows.
Why is Medtronic’s Diabetes unit economically different from its surgical businesses?
Diabetes combines pumps and smart delivery hardware with glucose monitoring and associated consumables, creating an ongoing patient-product relationship. Medical surgical is more directly connected to instruments, platforms, monitoring equipment, and therapies used around clinical procedures.
Can Medtronic deliver the operating leverage management described?
Recent operating profit moved favorably, but the latest sequential decline in gross profit and rise in selling and administrative expense set a demanding test. Leverage becomes visible when operating profit and cash flow advance with revenue rather than depending only on adjusted earnings performance.
How should investors read Medtronic’s repeated adjusted earnings beats?
The pattern shows consistent delivery relative to consensus, but it does not settle the quality of the underlying improvement. Gross profit, operating profit, and operating cash flow reveal whether those beats are accompanied by stronger business economics.
What is the MDT stock price today?
The last price recorded for Medtronic plc (MDT), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MDT price target?
The analyst consensus price target for Medtronic plc (MDT), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.
Sources: the source register lists the 43 figures on this page — 35 from Financial Modeling Prep (FMP), 5 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold MDT
Funds in our ETF coverage that list MDT among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| WisdomTree U.S. AI Enhanced Value Fund (AIVL) | 3.15% | |
| Eventide High Dividend ETF (ELCV) | 3.11% |
